Literature DB >> 3978248

Androgen metabolism and apocrine differentiation in human breast cancer.

W R Miller, J Telford, J M Dixon, A A Shivas.   

Abstract

Metabolism of (7 alpha-3H)testosterone has been measured in 111 human breast cancers and compared retrospectively with the degree of apocrine differentiation in the tumors. Cancers in which apocrine characteristics were a marked feature metabolized significantly more testosterone precursor than those in which apocrine features did not predominate. Higher metabolism was accounted for by increased conversion to 5 alpha-reduced products such as 5 alpha-dihydrotestosterone and 5 alpha-androstanediols.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3978248     DOI： 10.1007/bf01807652

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  19 in total

1.  Androgens in postmenopausal breast cancer: excretion, production and interaction with estrogens.

Authors:  J H Thijssen; J Poortman; F Schwarz
Journal:  J Steroid Biochem       Date:  1975-05       Impact factor: 4.292

Review 2.  Recent studies on the mechanism of action of testosterone.

Authors:  J D Wilson
Journal:  N Engl J Med       Date:  1972-12-21       Impact factor: 91.245

3.  Carcinoma of the breast. Histologic and clinical features of apocrine tumors.

Authors:  W J Frable; S Kay
Journal:  Cancer       Date:  1968-04       Impact factor: 6.860

4.  The control of the apocrine glands of the rabbit by steroid hormones.

Authors:  N A Wales; F J Ebling
Journal:  J Endocrinol       Date:  1971-12       Impact factor: 4.286

5.  Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features.

Authors:  G Mazoujian; G S Pinkus; S Davis; D E Haagensen
Journal:  Am J Pathol       Date:  1983-02       Impact factor: 4.307

6.  Factors affecting testosterone metabolism by human breast tissues.

Authors:  W R Miller; A A Shivas; A P Forrest
Journal:  Clin Oncol       Date:  1978-03

7.  Metabolism of dehydroepiandrosterone by hormone dependent and hormone independent human breast carcinoma.

Authors:  Y J Abul-Hajj
Journal:  Steroids       Date:  1975-10       Impact factor: 2.668

8.  The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4).

Authors:  E R Fisher; R M Gregorio; B Fisher; C Redmond; F Vellios; S C Sommers
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

9.  Apocrine differentiation in human mammary carcinoma.

Authors:  J A Mossler; T K Barton; A D Brinkhous; K S McCarty; J A Moylan; K S McCarty
Journal:  Cancer       Date:  1980-12-01       Impact factor: 6.860

10.  Steroid analysis of human apocrine secretion.

Authors:  J N Labows; G Preti; E Hoelzle; J Leyden; A Kligman
Journal:  Steroids       Date:  1979-09       Impact factor: 2.668
View more
  4 in total

Review 1.  Androgens in human breast carcinoma.

Authors:  Takashi Suzuki; Yasuhiro Miki; Kiyoshi Takagi; Hisashi Hirakawa; Takuya Moriya; Noriaki Ohuchi; Hironobu Sasano
Journal:  Med Mol Morphol       Date:  2010-08-04       Impact factor: 2.309

2.  AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.

Authors:  Dingxie Liu
Journal:  Cell Oncol (Dordr)       Date:  2020-01-13       Impact factor: 6.730

3.  Invasive apocrine carcinoma of the breast: a long term follow-up study of 34 cases.

Authors:  E S d'Amore; M J Terrier-Lacombe; J P Travagli; S Friedman; G Contesso
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

4.  Hormonal Homologies between Canine Mammary Cancer and Human Breast Cancer in a Series of Cases.

Authors:  Paloma Jimena de Andrés; Sara Cáceres; Juan Carlos Illera; Belén Crespo; Gema Silván; Felisbina Luisa Queiroga; Maria José Illera; Maria Dolores Pérez-Alenza; Laura Peña
Journal:  Vet Sci       Date:  2022-07-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.